From: "Pharma Sources" <cphichina@info.cphi-chinaedm.com>
Reply: "PharmaSources" <PharmaSources@imsinoexpo.com>
Date: Fri, 13 Aug 2021 15:57:37 +0800
Subject: PharmaSources E-Newsletter August 2021 Issue 1
What’s new in the Chinese pharma market: latest news, products and
events
View this e-mail
<Suspicious hyperlink> online
E-NEWSLETTER
August 2021
[register for free ]
<Suspicious hyperlink>
Home
<Suspicious hyperlink>
Products
<Suspicious hyperlink>
Suppliers
<Suspicious hyperlink>
News
<Suspicious hyperlink>
EDITOR'S PICK
<Suspicious hyperlink> NEW BREAKTHROUGH IN THE THERAPY OF HEMOPHILIA: CHINESE RECOMBINANT
COAGULATION FACTOR VIII HAS BEEN APPROVED FOR MARKETING
On July 23, according to latest announcement in the official website
of the National Medical Products Administration (NMPA), the
recombinant coagulation factor VIII (SCT800) for injection developed
by Shenzhou Cell Biotechnology (hereinafter referred to as Shenzhou
Cell) has been officially approved.
Read More
<Suspicious hyperlink>
MORE INDUSTRY INSIGHTS
* Drug Research and Development of Targeting STAT3: Next Outlet for
Antitumor Drugs
<Suspicious hyperlink>
* New Progress of Potential “Specific Drugs” for COVID-19: Masitinib
+ S2H97
<Suspicious hyperlink>
* Bispecific Antibodies – Key Developments in China
<Suspicious hyperlink>
HOT PRODUCTS
<Suspicious hyperlink>Rose Hip Extract
<Suspicious hyperlink>Andrographis Paniculata Extract
<Suspicious hyperlink>Mangostana Ectract
<Suspicious hyperlink>Rection Kettle
Jiahang Digital Automatic Analytic Balance
<Suspicious hyperlink>Two-side Tablet Inspection Machine
Source More Products
<Suspicious hyperlink>
WE WANT YOU!
Become a PHARMA PRODUCT WRITER
<Suspicious hyperlink> for
PharmaSources.com to Reach the Right Audience
Customer Service
(+86) 400 610 1188
PharmaSources@imsinoexpo.com
unsubscribe
<Suspicious hyperlink>